Alnylam and Ribopharma set to merge

07/7/2003 | Bloomberg

The merger of U.S.-based Alnylam Pharmaceuticals and German Ribopharma AG could create "a leading company in RNA interference," an executive said. The companies will work to develop a gene-deactivation technique that may result in drugs for cancer and other diseases

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Compliance and Ethics Director
Sysmex America, Inc.
Lincolnshire, IL
Director, Site Quality Management
Palm Springs, CA
Compliance Officer-Medical Products
W. L. Gore
Flagstaff, AZ
Director, Site Quality Management
Minneapolis, MN
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC